Ruxolitinib in 2020 and beyond
Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, discusses the use and impact of ruxolitinib for treating patients with myeloproliferative neoplasms…
Related Articles
Cytogenetic and molecular associations with outcomes in HR-MDS treated with HMAs plus venetoclax
Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the findings of a study exploring cytogenetic and molecular associations with outcomes…
Case Study: AML diagnosis, classification, risk-stratification and treatment
Sanam Loghavi and Naval Daver discuss the current approach to the diagnosis and classification, risk-stratification and treatment options for newly diagnosed AML in the context…
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares his excitement for the upcoming 10th World Congress on Controversies in Multiple Myeloma (COMy), which is…
Clinical significance of MRD status in patients with MM treated with CAR-T and T-cell engagers
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the clinical significance of measurable residual disease (MRD) in patients with relapsed/refractory (R/R) multiple myeloma (MM)…
Clinical significance of MRD status in patients with MM treated with CAR-T and T-cell engagers
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the clinical significance of measurable residual disease (MRD) in patients with relapsed/refractory (R/R) multiple myeloma (MM)…
PHOEBUS trial: oral fecal microbiotherapy for increasing OS in patients undergoing alloSCT
Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, introduces the PHOEBUS study (NCT05762211), a Phase IIb trial investigating the use of MaaT003,…
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox, MbChB, MD, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses an individualized approach to assessing potential risks of bone marrow…
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas, MD, University College London, London, UK, summarizes a talk on the role of donor lymphocyte infusion (DLI) in the post-allogenic stem cell transplant…
PTCy as GvHD prophylaxis: side effects, optimizing the dose, and the effect of dose-reduction
Rémy Duléry, MD, PhD, Saint-Antoine Hospital, Paris, France, outlines the main side effects associated with post-transplant cyclophosphamide (PTCy) as prophylaxis for graft-versus-host disease (GvHD) following…
Immune checkpoint inhibitors in MDS: the i4MDS consortium
Shahram Kordasti, MSc, MD, PhD, King’s College London, London, UK, shares his thoughts on the potential therapeutic capacity of immune checkpoint inhibitors (ICIs) in patients…